Kourong Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kourong Shi has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Qiaoli Zhai
Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
8 shared publications- Wei Fan
Department of Pharmacy, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
8 shared publications Huan Sun
Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
7 shared publications- Xin Wu
Fujian University of Traditional Chinese Medicine, Fuzhou, China
6 shared publications Juan Liu
Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China
5 shared publications- Siyuan Zhao
Department of Pharmacy & Innovative Chinese Medicine Research Institute, The Seventh People's Affiliated Hospital of Shanghai University of Traditional Chinese Medicine
4 shared publications
Latest Publications
- Open Access
- 26 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 225, 107617
Corrigendum to “iRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma” [European Journal of Pharmaceutical Sciences 224 (2026) 107599]
- 26 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 225, 107617
Open AccessCorrigendum to “iRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma” [European Journal of Pharmaceutical Sciences 224 (2026) 107599]
- Open Access
- 2 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 224, 107599
iRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma
- 2 July 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 224, 107599
Open AccessiRGD-modified peptide–drug conjugate improves brain delivery and antitumor efficacy in glioblastoma
- Open Access
- 26 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 781
Anthraquinone-Loaded Liposomes for TAM Reprogramming in Triple-Negative Breast Cancer: Mechanistic Rationale, Delivery Logic, and Translational Challenges
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by limited actionable targets, early recurrence, metastatic propensity, and variable responses to immune checkpoint blockade. Therapeutic resistance is closely associated with myeloid immunosuppression, in which tumor-associated macrophages (TAMs) promote T-cell exclusion, stromal remodeling, angiogenesis, metabolic dysfunction, and resistance to cytotoxic and immune-based therapies. Anthraquinone compounds, including emodin, aloe-emodin, rhein, and chrysophanol, may support TAM reprogramming by regulating tumor-cell stress responses, endoplasmic reticulum stress, immunogenic cell death-associated signaling, redox balance, immunometabolism, and STAT3/NF-κB-related inflammatory pathways. However, poor aqueous solubility, heterogeneous biodistribution, unstable systemic exposure, and potential off-target toxicity limit their translational development. Liposomal delivery offers a formulation strategy to improve solubilization, biodistribution, TAM-associated uptake/engagement, intracellular release, and therapeutic exposure windows. This review discusses anthraquinone-loaded liposomes for TAM reprogramming in TNBC by integrating mechanistic rationale, evidence boundaries, delivery logic, formulation determinants, and translational challenges, with particular attention to stress chaperone proteins, lipid composition, vesicle lamellarity, membrane phase state, responsive release, clinically relevant liposomal formulations, and clinical developability. Overall, anthraquinone-loaded liposomes are better positioned as immune microenvironment recalibration platforms or synergistic modulators in combination therapy rather than as standalone cytotoxic agents for TNBC.
- 26 June 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 781
Open AccessAnthraquinone-Loaded Liposomes for TAM Reprogramming in Triple-Negative Breast Cancer: Mechanistic Rationale, Delivery Logic, and Translational Challenges
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by limited actionable targets, early recurrence, metastatic propensity, and variable responses to immune checkpoint blockade. Therapeutic resistance is closely associated with myeloid immunosuppression, in which tumor-associated macrophages (TAMs) promote T-cell exclusion, stromal remodeling, angiogenesis, metabolic dysfunction, and resistance to cytotoxic and immune-based therapies. Anthraquinone compounds, including emodin, aloe-emodin, rhein, and chrysophanol, may support TAM reprogramming by regulating tumor-cell stress responses, endoplasmic reticulum stress, immunogenic cell death-associated signaling, redox balance, immunometabolism, and STAT3/NF-κB-related inflammatory pathways. However, poor aqueous solubility, heterogeneous biodistribution, unstable systemic exposure, and potential off-target toxicity limit their translational development. Liposomal delivery offers a formulation strategy to improve solubilization, biodistribution, TAM-associated uptake/engagement, intracellular release, and therapeutic exposure windows. This review discusses anthraquinone-loaded liposomes for TAM reprogramming in TNBC by integrating mechanistic rationale, evidence boundaries, delivery logic, formulation determinants, and translational challenges, with particular attention to stress chaperone proteins, lipid composition, vesicle lamellarity, membrane phase state, responsive release, clinically relevant liposomal formulations, and clinical developability. Overall, anthraquinone-loaded liposomes are better positioned as immune microenvironment recalibration platforms or synergistic modulators in combination therapy rather than as standalone cytotoxic agents for TNBC.
- Open Access
- 2 February 2026
- Published by Springer Nature in Thrombosis Journal
- Vol. 24 (1)
Pulmonary origin and risk assessment of cancer-associated thrombosis
Cancer-associated thrombosis (CAT) is a serious complication frequently observed in patients with cancer; however, its exact mechanism is not yet fully und
- 2 February 2026
- Published by Springer Nature in Thrombosis Journal
- Vol. 24 (1)
Open AccessPulmonary origin and risk assessment of cancer-associated thrombosis
Cancer-associated thrombosis (CAT) is a serious complication frequently observed in patients with cancer; however, its exact mechanism is not yet fully und
- 13 January 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (4) , 104160
A novel bicyclic peptide-drug conjugate of 3-fluoro-10-hydroxy-evodiamine for targeted colorectal cancer therapy
- 13 January 2026
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 115 (4) , 104160
A novel bicyclic peptide-drug conjugate of 3-fluoro-10-hydroxy-evodiamine for targeted colorectal cancer therapy
- 14 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 169, 109382
Peptide–drug conjugates: Emerging strategies in glioma therapy
- 14 December 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 169, 109382
Peptide–drug conjugates: Emerging strategies in glioma therapy
- Open Access
- 11 December 2025
- Published by Springer Nature in Drugs in R&D
- Vol. 25 (4) , 289-307
Omadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative effects. It was found that the metabolism of omadacycline does not rely on UDP-glucosyltransferase or cytochrome P450 enzymes, which gives it a clear advantage in terms of drug interactions, bioavailability, and metabolic stability. The review offers a thorough analysis of the many elements influencing the pharmacokinetics of omadacycline, including its intrinsic properties, individual differences, dietary influences, and possible drug interactions. To achieve maximum efficacy and safety in clinical practice, a thorough understanding of the pharmacokinetic properties of omadacycline is essential, which helps to better customize dosing regimens and maximize therapeutic outcomes.
- 11 December 2025
- Published by Springer Nature in Drugs in R&D
- Vol. 25 (4) , 289-307
Open AccessOmadacycline Pharmacokinetics: Characteristics, Contributing Factors, and Clinical Significance
Omadacycline is a novel tetracycline with a wide range of antibacterial activity. A comprehensive understanding of the factors influencing its metabolic processes is essential to optimize its therapeutic benefits and minimize any potential negative effects. It was found that the metabolism of omadacycline does not rely on UDP-glucosyltransferase or cytochrome P450 enzymes, which gives it a clear advantage in terms of drug interactions, bioavailability, and metabolic stability. The review offers a thorough analysis of the many elements influencing the pharmacokinetics of omadacycline, including its intrinsic properties, individual differences, dietary influences, and possible drug interactions. To achieve maximum efficacy and safety in clinical practice, a thorough understanding of the pharmacokinetic properties of omadacycline is essential, which helps to better customize dosing regimens and maximize therapeutic outcomes.
- 13 May 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (11) , 4103-4116
Interplay between the gut microbiota, its metabolites and carcinogens
The gut microbiota is a complex and dynamic community of microorganisms that reside in the gastrointestinal tract, playing a critical role in the host. It produces many metabolites, such as bile acids, which play an important role in the metabolism of the host. One area of particular interest is its involvement in the development and treatment of cancer. Carcinogens, which are substances known to promote cancer formation and development, are present in various sources in our daily lives, including cigarettes, barbecues, and moldy foods. The types, amounts, and metabolism of carcinogens have been closely linked to cancer risk, underscoring the importance of understanding their interplay with the gut microbiota. Numerous studies have demonstrated significant differences in the composition and function of the gut microbiota in individuals with cancer compared to healthy individuals. The gut microbiota and its metabolites have been shown to influence the metabolism of various carcinogens, thereby affecting cancer progression. While much attention has been paid to the relationship between the gut microbiota and cancer risk, the potential interplay between the gut microbiota and carcinogens has received less focus. This review aims to emphasize the importance of exploring the interplay between the gut microbiota with its metabolites and carcinogens in cancer development and therapy. By uncovering the mechanisms of the interplay, new approaches for cancer prevention and treatment can be developed.
- 13 May 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (11) , 4103-4116
Interplay between the gut microbiota, its metabolites and carcinogens
The gut microbiota is a complex and dynamic community of microorganisms that reside in the gastrointestinal tract, playing a critical role in the host. It produces many metabolites, such as bile acids, which play an important role in the metabolism of the host. One area of particular interest is its involvement in the development and treatment of cancer. Carcinogens, which are substances known to promote cancer formation and development, are present in various sources in our daily lives, including cigarettes, barbecues, and moldy foods. The types, amounts, and metabolism of carcinogens have been closely linked to cancer risk, underscoring the importance of understanding their interplay with the gut microbiota. Numerous studies have demonstrated significant differences in the composition and function of the gut microbiota in individuals with cancer compared to healthy individuals. The gut microbiota and its metabolites have been shown to influence the metabolism of various carcinogens, thereby affecting cancer progression. While much attention has been paid to the relationship between the gut microbiota and cancer risk, the potential interplay between the gut microbiota and carcinogens has received less focus. This review aims to emphasize the importance of exploring the interplay between the gut microbiota with its metabolites and carcinogens in cancer development and therapy. By uncovering the mechanisms of the interplay, new approaches for cancer prevention and treatment can be developed.
- 21 December 2024
- Published by Springer Nature in Investigational New Drugs
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects, providing a new approach for colorectal cancer treatment. Fluorouracil was hydroxylated and conjugated with methotrexate to form a 5-fluorouracil-methotrexate conjugate (MF). This was complexed with sulfobutyl ether-beta-cyclodextrin (MF-SEBCD) using a stirring method to create an injectable formulation. In vitro studies assessed the conversion of MF-SEBCD in plasma and its antitumor activity. In vivo studies examined antitumor activity, preliminary safety, pharmacokinetics, and tissue distribution. MF was synthesized with a 25% yield and purity above 95%. The water solubility of MF increased by 92-fold with MF-SEBCD preparation. In vitro, MF-SEBCD effectively converted into Fu in plasma and showed strong antitumor activity, with IC50 values of 0.51, 1.29, and 1.26 mu M for MC38, HT29, and 4T1 cells, respectively. In vivo, MF-SEBCD achieved a tumor inhibition rate of 57.08%. Pharmacokinetic studies showed that MF-SEBCD extended Fu's half-life to 47 min, nearly double that of Fu injection. Tissue distribution analysis confirmed improved tumor targeting. MF-SEBCD effectively prolongs Fu's half-life, enhances tumor targeting, increases antitumor efficacy, and reduces side effects, offering a promising approach for colorectal cancer treatment.
- 21 December 2024
- Published by Springer Nature in Investigational New Drugs
5-Fluorouracil-methotrexate conjugate enhances the efficacy of 5-fluorouracil in colorectal cancer therapy
To extend the short half-life of fluorouracil (Fu), enhance its tumor targeting, improve efficacy, and reduce side effects, providing a new approach for colorectal cancer treatment. Fluorouracil was hydroxylated and conjugated with methotrexate to form a 5-fluorouracil-methotrexate conjugate (MF). This was complexed with sulfobutyl ether-beta-cyclodextrin (MF-SEBCD) using a stirring method to create an injectable formulation. In vitro studies assessed the conversion of MF-SEBCD in plasma and its antitumor activity. In vivo studies examined antitumor activity, preliminary safety, pharmacokinetics, and tissue distribution. MF was synthesized with a 25% yield and purity above 95%. The water solubility of MF increased by 92-fold with MF-SEBCD preparation. In vitro, MF-SEBCD effectively converted into Fu in plasma and showed strong antitumor activity, with IC50 values of 0.51, 1.29, and 1.26 mu M for MC38, HT29, and 4T1 cells, respectively. In vivo, MF-SEBCD achieved a tumor inhibition rate of 57.08%. Pharmacokinetic studies showed that MF-SEBCD extended Fu's half-life to 47 min, nearly double that of Fu injection. Tissue distribution analysis confirmed improved tumor targeting. MF-SEBCD effectively prolongs Fu's half-life, enhances tumor targeting, increases antitumor efficacy, and reduces side effects, offering a promising approach for colorectal cancer treatment.
- Open Access
- 10 August 2024
- Published by Elsevier in Pharmacological Research
- Vol. 207, 107341
Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions
- 10 August 2024
- Published by Elsevier in Pharmacological Research
- Vol. 207, 107341
Open AccessNatural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions